Looking for something to read for the holidays?
In 2024, Scantox Neuro developed various new in vitro and in vivo models and methods, and existing ones were constantly improved. Our currently ongoing and planned R&D projects are now presented in the new R&D corner.
The results of Scantox Neuro’s steady R&D efforts lead to 3 peer-reviewed publications and 11 posters presented at scientific conferences around the world. Furthermore, Scantox Neuro participated in several other publications as service provider and is mentioned as such.
Publications
Motor deficits and brain pathology in the Parkinson’s disease mouse model hA53Ttg (Breznik et al., 2024)
The publication presents a comprehensive characterization of the tg(THY1-SNCA*A53T)M53Sud (hA53Ttg) mouse model, developed by T. C. Südhof and colleagues. We are showing that hA53Ttg mice exhibit progressive motor symptoms, increased levels of hα-syn, highly increased levels of α-syn pSer129 starting at very early age, fiber-like structures in the cortex, increased neuroinflammation and axonal degeneration at later ages. Our findings suggest that hA53Ttg mice are a valuable tool for Parkinson’s disease research as it accurately models some of the main features of this devastating disease.
Gadolinium Presence in Rat Skin: Assessment of Histopathologic Changes Associated with Small Fiber Neuropathy (Boyken et al., 2024)
The collaborative publication investigates signs of small fiber neuropathy (SFN) in rat foot pads by quantification of the intraepidermal nerve fibre density (IENFD) after administration of multiple gadolinium-based contrast agents (GBCAs). It further evaluates the gadolinium concentration, the chemical species, and clearance. The results show that there were no signs of SFN in rat foot pads using multiple dosing regimens at two time points after administration of GBCAs. Macrocyclic GBCAs exhibited lower levels of gadolinium in the skin and were effectively eliminated within 5 weeks compared with linear gadodiamide, and intact macrocyclic GBCA was detected in sweat glands.
Effect of astaxanthin in type-2 diabetes -induced APPxhQC transgenic and NTG mice (Babalola et al., 2024)
The collaborative publication investigates the combinatory effects of human glutaminyl cyclase activity (pyroglutamylation) and metabolic dysfunction in Alzheimer’s disease pathology by inducing type 2 diabetes (T2D) in the pGlu-Aβ-expressing APPxhQC mouse model. We demonstrate that T2D induction in APPxhQC mice poses additional risk for Alzheimer’s disease pathology as seen by increased Aβ deposition. Although astaxanthin treatment reduced Aβ expression in T2D-induced APPxhQC mice and rescued T2D-induced memory impairment in non-transgenic mice, astaxanthin treatment alone may not be effective in cases of T2D comorbidity and Alzheimer’s disease.
For more publications from the Scantox group, please check our website.
Posters
Amyotrophic Lateral Sclerosis
- In Vitro Systems Targeting TDP-43 Translocation, Stress Granules, and Stathmin-2 Splicing
- Comparative Analysis of In Vitro Systems for TDP-43 Pathology
- Characterization of an Inducible AAV9-hTDP-43 Mouse Model for ALS
Alzheimer’s Disease and Aging
- Accelerated Aging and Senescence in Cerebral Organoids
- LPS and Pre-Aggregated Aβ1-42 Lead to an Increased Neuroinflammatory Response in Cerebral Organoids
Parkinson’s Disease
- AAV-Human A53T-Mutated Synuclein Disrupts Nigro-Striatal System in Mice
- Viral Gene Delivery Approach to Mimic α-Synuclein Pathology in a Preclinical Model for Parkinson`s Disease
- Behavioral and Histological Hallmarks of an Intrastriatal Rotenone Mouse Model for Parkinson’s Disease
Migraine
Depression
Gene Therapy
Contact us to discuss your collaboration options with Scantox Neuro.
